BioScrip, Inc. (NASDAQ:BIOS) CFO Stephen Deitsch purchased 10,000 shares of BioScrip stock in a transaction on Thursday, November 9th. The shares were acquired at an average cost of $2.03 per share, for a total transaction of $20,300.00. Following the completion of the transaction, the chief financial officer now owns 10,000 shares of the company’s stock, valued at $20,300. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink.
BioScrip, Inc. (BIOS) opened at $2.16 on Tuesday. BioScrip, Inc. has a 12-month low of $0.98 and a 12-month high of $3.39. The company has a current ratio of 1.91, a quick ratio of 1.60 and a debt-to-equity ratio of -6.11.
BioScrip (NASDAQ:BIOS) last posted its earnings results on Thursday, November 2nd. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). The firm had revenue of $198.70 million for the quarter, compared to analyst estimates of $202.91 million. During the same quarter in the prior year, the firm posted ($0.12) earnings per share. The company’s quarterly revenue was down 11.5% on a year-over-year basis. analysts expect that BioScrip, Inc. will post -0.63 earnings per share for the current year.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Roanoke Asset Management Corp NY lifted its position in shares of BioScrip by 72.9% during the second quarter. Roanoke Asset Management Corp NY now owns 403,280 shares of the company’s stock worth $1,095,000 after purchasing an additional 170,000 shares in the last quarter. UBS Group AG lifted its position in shares of BioScrip by 14.0% during the first quarter. UBS Group AG now owns 271,209 shares of the company’s stock worth $461,000 after purchasing an additional 33,211 shares in the last quarter. Skylands Capital LLC acquired a new position in shares of BioScrip during the third quarter worth $272,000. Alta Fundamental Advisers LLC lifted its position in shares of BioScrip by 36.9% during the second quarter. Alta Fundamental Advisers LLC now owns 3,035,164 shares of the company’s stock worth $8,240,000 after purchasing an additional 818,000 shares in the last quarter. Finally, FMR LLC lifted its position in shares of BioScrip by 10.8% during the second quarter. FMR LLC now owns 5,323,231 shares of the company’s stock worth $14,453,000 after purchasing an additional 520,231 shares in the last quarter. 83.00% of the stock is currently owned by institutional investors and hedge funds.
A number of research analysts have weighed in on BIOS shares. BidaskClub cut shares of BioScrip from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 1st. SunTrust Banks, Inc. reaffirmed a “buy” rating and set a $3.00 price target on shares of BioScrip in a research report on Friday, November 3rd. Jefferies Group LLC reaffirmed a “buy” rating and set a $4.00 price target (up from $3.00) on shares of BioScrip in a research report on Thursday, August 10th. ValuEngine raised shares of BioScrip from a “sell” rating to a “hold” rating in a research report on Monday, August 14th. Finally, Zacks Investment Research cut shares of BioScrip from a “buy” rating to a “hold” rating in a research report on Monday, August 14th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. BioScrip has a consensus rating of “Hold” and a consensus price target of $3.60.
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
Receive News & Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related companies with MarketBeat.com's FREE daily email newsletter.